Navigation Links
Phlo Affiliate Names Director Of Marketing
Date:11/7/2007

JACKSONVILLE, Fla., Nov. 7 /PRNewswire-FirstCall/ -- An affiliate of Phlo Corporation (OTC: PHLC) (the "Company") announced today that it has hired Dan Reynolds as its Director of Marketing. Mr. Reynolds is a marketing and communications expert with nearly 30 years of experience in the United States and Canada. Mr. Reynolds will support the branding, marketing, and communications functions of the Company, headed by Rudy Prajza, Chief Marketing Officer.

Mr. Reynolds' professional experience includes work in over 14 industries such as food and beverages, financial services, hospitality, telecommunications, automobiles, health and beauty aids, and petroleum. His direct working experience includes such internationally-recognized organizations as Gillette, Subway, Sears, Royal Bank, BMW, Honda, the Government of Canada, Brita (water purifiers), and Petro-Canada, among others.

Mr. Reynolds has worked with a number of marketing communications companies including Saatchi & Saatchi, DMB&B, Foote, Cone & Belding, and MacLaren-McCann Advertising.

AQUISS(TM) features the Company's Instant Nano Hydration and Cell Armor technologies, providing instant, direct delivery of rehydration and cell- repair-and-protection payloads into the bloodstream beginning through the membranes of the mouth. These Instant Nano Hydration and Cell Armor technologies help provide sustained wellness necessary for life's performances and vigorous longevity. In addition, the Company's nano-encapsulation technology prevents the destruction of its active payloads in the stomach.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.


'/>"/>
SOURCE Phlo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Phlo Affiliate Reports Expanded Coverage to Oregon Border
2. Phlo Affiliate Reports AQUISS to be Sold in 450 7-Eleven Stores
3. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
4. Phlo Affiliate to Launch AQUISS(TM) on East Coast
5. KGI Names Kerry Howell Vice President for Advancement
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. CryoLife Names Philip Theodore as Vice President, General Counsel
10. Genstar Names Michael Hurt to Its Strategic Advisory Board
11. PPD Names Daniel Darazsdi as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... FRANCISCO , Feb. 24, 2017 Symic ... is developing a new category of therapeutics, announced today ... of SB-030 in peripheral artery disease. The trial will ... administered single-use therapeutic, in the reduction of restenosis following ... this critical development milestone for SB-030," said Nathan ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive small ... FireflySci had the goal of bringing their powerful cuvette and spectrophotometer calibration ... path that FireflySci is going on as they add yet another mark on the ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is formalizing ... an array of biochemical analyses critical for Lead Discovery. The company’s Lead ... SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor residence ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
Breaking Biology News(10 mins):